Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib.

Castelino FV, Bhattacharyya S, Varga J.

Curr Rheumatol Rep. 2009 Jul;11(3):161-3. No abstract available.

PMID:
19604458
2.

A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.

Bibi Y, Gottlieb AB.

J Am Acad Dermatol. 2008 Oct;59(4):654-8. doi: 10.1016/j.jaad.2008.04.034. Epub 2008 Jun 20. Review.

PMID:
18571768
3.

Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.

Distler JH, Distler O.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i48-51. doi: 10.1136/ard.2009.120196. Review.

4.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
5.

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.

Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M.

Arthritis Rheum. 2008 Aug;58(8):2528-37. doi: 10.1002/art.23698.

6.

Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Tolomeo M, Dieli F, Gebbia N, Simoni D.

Anticancer Agents Med Chem. 2009 Oct;9(8):853-63. Review.

PMID:
19538165
8.

The second generation of BCR-ABL tyrosine kinase inhibitors.

Tauchi T, Ohyashiki K.

Int J Hematol. 2006 May;83(4):294-300. Review.

PMID:
16757427
9.

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M.

Blood. 2003 Jan 15;101(2):664-72. Epub 2002 Sep 5.

10.

Is imatinib mesylate a promising drug in systemic sclerosis?

van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM.

Arthritis Rheum. 2008 Aug;58(8):2549-52. doi: 10.1002/art.23648.

11.

[Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].

Le Nouail P, Viseux V, Chaby G, Billet A, Denoeux JP, Lok C.

Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):686-8. French.

PMID:
17053739
12.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.

13.

Resistance to tyrosine kinase inhibitors: calling on extra forces.

Cools J, Maertens C, Marynen P.

Drug Resist Updat. 2005 Jun;8(3):119-29. Review.

PMID:
15869901
14.

[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].

Martínez C.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:69-71. Review. Spanish.

PMID:
21381292
15.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

16.

Imatinib mesylate, the first molecularly targeted gene suppressor.

Pindolia VK, Zarowitz BJ.

Pharmacotherapy. 2002 Oct;22(10):1249-65. Review.

PMID:
12389876
17.

New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Kimura S, Ashihara E, Maekawa T.

Curr Pharm Biotechnol. 2006 Oct;7(5):371-9. Review.

PMID:
17076652
18.
19.

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.

Jabbour E, Cortes J, Kantarjian H.

Curr Opin Oncol. 2006 Nov;18(6):578-83. Review.

PMID:
16988578
20.

All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line.

Robert C, Apàti A, Chomienne C, Papp B.

Leuk Res. 2008 Feb;32(2):343-6. Epub 2007 Oct 29.

PMID:
17915318

Supplemental Content

Support Center